RecruitingNot Applicable

A Prospecitve Multicenter, Observational Registry Study

China3,000 participantsStarted 2026-02-27

Plain-language summary

This is a prospective, multicenter, observational registry study designed to collect data to deepen the understanding of CKD therapeutics, changes in clinical practice, cardiorenal risk outcomes and differences in treatment approaches in Chinese CKD patients.

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female patients aged ≥18 years. * Willing and able to provide written informed consent to participate in the study. * Confirmed CKD diagnosis at enrolment, defined by at least one of the following: * eGFR \<60 mL/min/1.73 m² for ≥3 months, OR * Evidence of kidney damage (e.g., UACR ≥30 mg/g or UPCR ≥150 mg/g, structural abnormality on imaging, or kidney biopsy findings consistent with chronic kidney injury) persisting for ≥3 months Exclusion Criteria: * Having a life-threatening comorbidity with life expectancy \< 2 years. * Severe cardiac disease: life-threatening arrhythmias, or recent MACE (Myocardial infarction (MI), stroke, CV death) within the past 3 months. * Pregnant or breastfeeding women. * Currently enrolled in any interventional clinical trial or receiving investigational therapy within 3 months of enrollment. * Presenting with ESRD, RRT, acute kidney injury (AKI), acute kidney disease (i.e., kidney injury or a decline in renal function persisting for ≤3 months) as a primary disease condition at enrollment.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Proportion of CKD patients with HP, HF, HTN, and HK at baseline, respectively

Timeframe: baseline

Adoption rate of medications (e.g., Endothelin receptor antagonists [ERA], MRA, RASi, SGLT2i)

Timeframe: Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

Timeframe: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

Timeframe: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

Timeframe: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

Timeframe: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

Timeframe: Week 0 to week 96

Trial details

NCT IDNCT07481526

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2028-12-30

Contact for this trial

AstraZeneca Clinical Study Information Center

1-877-240-9479 information.center@astrazeneca.com

View on ClinicalTrials.gov More Chronic Kidney Disease trials

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Proportion of CKD patients with HP, HF, HTN, and HK at baseline, respectively

Timeframe: baseline

Adoption rate of medications (e.g., Endothelin receptor antagonists [ERA], MRA, RASi, SGLT2i)

Timeframe: Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

Timeframe: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

Timeframe: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

Timeframe: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

Timeframe: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

Timeframe: Week 0 to week 96